Attribute	Specification
Brand	BioSynLab Research Compounds
Product Name	AMT (α-Methyltryptamine)
IUPAC Name	1-(1H-indol-3-yl)propan-2-amine
Synonyms	alpha-Methyltryptamine, IT-290, 3-(2-aminopropyl)indole, AMT Freebase
CAS Number	299-26-3
Molecular Formula	C₁₁H₁₄N₂
Molecular Weight	174.24 g/mol
Dosage Form	Compressed Pellets (Tablets)
Unit Dose	25mg ± 0.5mg
Pellet Dimensions	5mm diameter × 2.5mm height
Pellet Weight	75mg total (25mg API + 50mg excipients)
Purity	≥98.0% (HPLC Verified)
Appearance	Off-White to Light Tan Round Pellets
Imprint	BioSynLab “AMT” debossing
Packaging	Blister packs (10 pellets per sheet)
Storage	-20°C, Desiccated, Light Protected
Excipients	Microcrystalline cellulose, Pregelatinized starch, Magnesium stearate
Documentation	COA, HPLC, Dissolution Profile, MSDS, Stability Data
Shipping	Cryogenic Packaging Available
Origin	EU/GMP Certified Manufacturing

AMT Pellets 25mg (α-Methyltryptamine) | Research-Grade Monoamine Modulator | BioSynLab

BioSynLab presents pharmaceutical-grade AMT (α-methyltryptamine) pellets in a 25mg precision-dosed format for advanced neuropharmacological research and monoaminergic system investigations. As a structurally unique tryptamine featuring alpha-methyl substitution, AMT serves as a critical reference compound for studying indirect serotonin agonism, monoamine oxidase inhibition, and structure-activity relationships within the indolealkylamine scaffold.

Chemical Architecture & Pharmacological Distinctions

α-Methyltryptamine represents a fundamental structural modification of the tryptamine backbone, introducing a methyl substituent at the alpha carbon (C-2 position of the side chain). This stereogenic center creates chirality (R- and S-enantiomers), though commercial preparations typically contain the racemic mixture of both configurations.

Key Structural Features:

• Alpha-Methyl Substitution: Creates steric hindrance affecting metabolic degradation via monoamine oxidase (MAO) enzymes, significantly prolonging duration of action compared to unsubstituted tryptamine
• Primary Amine: Unlike N,N-dialkyltryptamines (DMT, DET, DPT), the primary amine confers MAO substrate properties and reduced 5-HT2A affinity, creating distinct pharmacodynamic profiles
• Indole Nucleus: Maintains the essential tryptophan-derived chromophore for UV detection and fluorescence properties

Physicochemical Properties:

• pKa (amine): ~9.8 (protonated at physiological pH)
• LogP (calculated): 2.1 (moderate lipophilicity)
• Chirality: Racemic mixture (R/S enantiomers)
• Melting Point: 92-94°C (freebase), 192-194°C (hydrochloride)

Pellet Formulation & Pharmaceutical Engineering

Our 25mg AMT pellets utilize direct compression technology with pharmaceutical-grade excipients optimized for research handling and dosing precision:

Formulation Composition:

• Active Pharmaceutical Ingredient: α-Methyltryptamine freebase – 25.0mg (33.3% w/w)
• Diluent: Microcrystalline cellulose (Avicel PH-102) – 35.0mg (46.7% w/w)
• Binder: Pregelatinized starch (Starch 1500) – 12.5mg (16.7% w/w)
• Lubricant: Magnesium stearate – 2.5mg (3.3% w/w)

Physical Specifications:

• Hardness: 5-7 kp (optimal for handling)
• Friability: <0.3% (minimal dust generation)
• Disintegration: 20-35 minutes (simulated gastric fluid)
• Dissolution: >75% API release within 30 minutes
• Weight Uniformity: RSD <5% (n=20, USP <905>)

Pellet Geometry:
The 5mm × 2.5mm round convex design facilitates:

• Accurate dispensing with laboratory forceps
• Reduced chipping during transport
• Easy identification via debossed “AMT” marking
• Compatible sizing with automated counting equipment

Blister Packaging & Stability Preservation

AMT 25mg pellets are sealed in pharmaceutical-grade aluminum blisters providing superior environmental protection:

Barrier Properties:

• Cold-form aluminum (CFF) trilaminate construction
• Water vapor transmission: <0.01 g/m²/day
• Oxygen exclusion: <0.1 cc/m²/day
• Light blocking: >99% (UV-Vis spectrum)
• Child-resistant push-through design

Secondary Packaging:

• Tamper-evident cartons with holographic seals
• Indicating desiccant (non-contact compartment)
• Batch-coded labeling with QR-linked COA
• Temperature indicators (irreversible color-change)

Stability Profile:

• Long-term: 24 months at -20°C (primary stability)
• Accelerated: 6 months at 40°C/75% RH (ICH Q1A)
• In-use: 30 days at room temperature once blister opened

Analytical Verification & Quality Control

Each BioSynLab AMT batch undergoes comprehensive release testing:

Identity Confirmation:

• HPLC-UV (280nm): ≥98.0% purity, retention time matching
• ¹H NMR (500MHz, CD₃OD):
  • Indole N-H: δ 10.2 (br s)
  • Aromatic H-4, H-5, H-6, H-7: δ 6.8-7.6 (m)
  • α-CH: δ 3.4 (m, 1H)
  • CH₃: δ 1.3 (d, 3H, J=6.5Hz)
  • CH₂: δ 3.0 (dd, 1H), 2.8 (dd, 1H)
• Chiral HPLC: Enantiomeric ratio confirmation (racemic)
• LC-MS/MS: [M+H]⁺ at m/z 175.1, fragments at m/z 144, 130

Pellet-Specific Testing:

• Content uniformity: 10 pellets, RSD <6%
• Dissolution profile: Apparatus 2, 50 RPM, pH 1.2 buffer
• Disintegration: USP <701>, 37°C
• Hardness & friability: USP <1216>

Impurity Profile:

• Related substances: <2.0% total impurities
• Individual impurities: <0.5% each
• Residual solvents: Meets ICH Q3C
• Heavy metals: <10 ppm (ICP-MS)

Research Applications & Scientific Utility

AMT 25mg pellets enable standardized dosing for diverse research applications:

Neuropharmacology:

• Monoamine oxidase inhibition (MAOI) studies (competitive vs. mechanism-based)
• Serotonin releasing agent (SRA) activity quantification
• 5-HT1A/5-HT2A receptor binding comparisons vs. tryptamine and DMT
• Norepinephrine/dopamine reuptake inhibition profiling

Metabolic Biochemistry:

• CYP450 metabolism (CYP2D6 substrate identification)
• Phase II conjugation (glucuronidation, sulfation pathways)
• Enantioselective metabolism (R- vs. S-AMT biotransformation)
• Drug-drug interaction potential (MAO substrate competition)

Behavioral Neuroscience:

• Locomotor activity assays (rodent open field)
• Drug discrimination paradigms (stimulus generalization)
• Thermoregulation studies (hypothermic response)
• Head-twitch response quantification (5-HT2A mediated)

Forensic & Analytical:

• GC-MS method development (derivatization requirements)
• LC-MS/MS forensic libraries (retention time databases)
• Chiral separation method validation
• Stability in biological matrices (blood, urine, hair)

Comparative Pharmacology:

• Tryptamine analog series structure-activity relationships
• Alpha-substitution effects on duration and potency
• Primary vs. tertiary amine pharmacodynamic comparisons

Global Distribution & Discrete Logistics

BioSynLab operates strategic distribution hubs ensuring compliant, rapid delivery:

Shipping Configurations:

• Standard: -20°C with phase-change materials, 5-7 days
• Express: Temperature-monitored, 2-3 days (DHL/FedEx)
• Cryogenic: Liquid nitrogen vapor (-150°C) for bulk orders
• Discrete: Unmarked packaging, generic return addresses